Type your tag names separated by a space and hit enter

    Trovafloxacin

    Edina Avdic, Pharm.D., Paul A. Pham, Pharm.D.
    Trovafloxacin is a topic covered in the Johns Hopkins ABX Guide.

    To view the entire topic, please or purchase a subscription.

    Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

    Johns Hopkins Guides

    -- The first section of this topic is shown below --

    INDICATIONS

    FDA

    • Before pulled from the U.S. market for hepatotoxicity reasons, the use of trovafloxacin was reserved for use only if the patient meets all of the following criteria:
      • Has at least one of the following infections that is judged by the treating physician to be serious and life- or limb-threatening:
      • Receives initial therapy in an in-patient heath care facility (i.e., hospital or long-term nursing care facility).
      • The treating physician believes that, even given the new safety information, the benefit of the product for the patient outweighs the potential risk.
      • Use of trovafloxacin was limited to 14 days or less.

    NON-FDA APPROVED USES

    -- To view the remaining sections of this topic, please or purchase a subscription --

    Last updated: May 1, 2017

    Citation

    * When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
    TY - ELEC T1 - Trovafloxacin ID - 540567 A1 - Avdic,Edina,Pharm.D. AU - Pham,Paul,Pharm.D. Y1 - 2017/05/01/ BT - Johns Hopkins ABX Guide UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540567/all/Trovafloxacin PB - The Johns Hopkins University DB - Johns Hopkins Guide DP - Unbound Medicine ER -